Calico (company)
Search results
Apr 25, 2024 · We are at the forefront of developing a new class of therapeutics that may address the root cause of many diseases of aging. By selectively eliminating or modulating senescent cells, we may restore aging or damaged tissues to a more functionally healthy state. Learn More.
WE ASPIRE TO DEVELOP TRANSFORMATIVE MEDICINES TO SLOW, HALT, OR REVERSE DISEASES OF AGING. Working at the frontier of biotechnology and medicine, our mission is to develop therapeutics to extend the period of one’s life unburdened by disease.
LEAD PRODUCT CANDIDATES. UNITY’s most advanced drug candidate, UBX1325, is currently being evaluated for the treatment of age-related diseases of the eye – including diabetic macular edema. The small molecule targets Bcl-xL, a protein that senescent cells rely on for survival.
May 14, 2024 · UNITY Biotechnology is developing therapeutics to slow, halt or reverse diseases of aging. UNITY's initial focus is on creating medicines that target cellular senescence and aging-related biology in ophthalmologic and neurologic diseases, while leveraging partnerships in growth areas with high unmet need.
Find the latest Unity Biotechnology, Inc. (UBX) stock quote, history, news and other vital information to help you with your stock trading and investing.
Unity Biotechnology designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells; and designs senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected.
Unity Biotechnology, Inc. is a publicly traded American biotechnology company that develops drugs that target senescent cells.
Dec 12, 2023 · ASPIRE is a multi-center, randomized, double-masked, active-controlled study designed to evaluate the safety and efficacy of UBX1325 in comparison to aflibercept in previously treated patients with active diabetic macular edema (DME) who are not achieving optimal benefit from standard of care.
Aug 12, 2022 · SOUTH SAN FRANCISCO, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced 12- and 18-week data from its Phase 2 BEHOLD study of UBX1325, a senolytic Bcl-xL inhibitor, in patients with diabetic ...
Apr 23, 2024 · SOUTH SAN FRANCISCO, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse...
